Securing Critical Materials for Resilient Biopharmaceutical Manufacturing

Key Takeaways

• Raw material security is a quality and patient-access issue, not simply a procurement or inventory challenge.

• Variability in cell culture media, trace elements, biological starting materials, and other process inputs can affect productivity and product-quality attributes.

• Specialized single-use components require risk-based evaluation of supplier controls, sterilization, integrity, compatibility, and extractables and leachables.

• Changing a raw material or supplier may require qualification, validation, analytical comparability, regulatory reporting, and, in some cases, additional nonclinical or clinical evidence.

• Resilient biopharmaceutical supply chains depend on criticality ranking, upstream traceability, supplier change notification, cross-functional governance, and prequalified backup options.

Modern biopharmaceutical manufacturing depends on a broad network of biological and chemical raw materials, cell culture media, enzymes, lipids, chromatography resins, filtration products, single-use components, and primary packaging. The value of an individual input may be modest relative to the value of the batch it supports, but that comparison can obscure its operational importance. A missing filter, an unavailable cell culture supplement, or an unsuitable connector can prevent a process from proceeding even when the facility, equipment, workforce, and other materials remain available. Vaccine-manufacturing supply chains, for example, require inputs ranging from cell banks and plasmids to chromatography membranes, bags, tubing, lipids, vials, and stoppers, illustrating how many distinct material categories must align to support production.¹

Material security therefore belongs within pharmaceutical quality risk management rather than procurement alone. Quality-risk principles explicitly encompass raw materials, solvents, excipients, and packaging and labeling materials used in biological and biotechnological products. They also connect product availability to patient protection when quality or manufacturing problems threaten supply. The relevant risk is not limited to whether a purchasing team can place an order. It includes whether a material of the required quality can be obtained, whether it will perform consistently in the process, and whether a replacement can be introduced without compromising the product or delaying manufacturing.²

Regulatory expectations reinforce that connection. A pharmaceutical company remains responsible for the quality of purchased materials and outsourced activities, including supplier assessment, definition of quality responsibilities, performance monitoring, and verification that incoming materials originate from approved sources within the agreed supply chain. Supplier management cannot be delegated away simply because a material is purchased through a distributor, sourced by a contract development and manufacturing organization (CDMO), or supported by a supplier certificate of analysis.³

This broader view changes the purpose of a raw material security program. The goal is not to eliminate every supply risk or to qualify multiple suppliers for every catalog item. It is to understand which materials and components exert the greatest influence on process continuity, product quality, and replacement complexity, and then apply controls proportionate to those risks. That requires coordinated decisions across quality, process development, manufacturing, engineering, regulatory affairs, supply chain, and other functions with relevant scientific or operational knowledge.²

The sensitivity of a bioprocess to its inputs extends beyond conventional measures of material identity and purity. Cell culture systems respond to the composition of their environment, and differences in media or media components can affect cell growth, viability, specific productivity, and the quality profile of the expressed therapeutic protein. A material may meet its established specification while still containing variation that matters to a particular cell line, product, or manufacturing process.⁴

Trace metals provide one example. Elements like copper and manganese participate in pathways that influence cell growth, protein expression, and glycosylation. Their concentrations may vary among lots of raw materials, creating a potential link between upstream material variability and downstream process or product outcomes. This does not mean that every change in elemental composition will affect every process. It means that manufacturers need enough process knowledge to identify which attributes warrant monitoring and how much variation the process can tolerate.⁵

A manufacturing investigation involving poloxamer 188 demonstrates how a material issue can remain hidden within a familiar input.⁶ Poor monoclonal antibody (mAb) cell culture performance occurred at two manufacturing sites with similar scales and equipment. The investigation traced the affected basal-media lots to a particular lot of poloxamer 188 and identified polypropylene oxide, a low-molecular-weight intermediate associated with poloxamer synthesis, in the suspect material. Spiking studies supported a cytostatic effect. The problem was not simply that the correct material had failed to arrive; a nominally correct material had arrived and behaved differently in the process.

Cases of this kind support greater attention to material genealogy, lot-to-lot trends, and process-relevant characterization. They also show the limits of assessing materials exclusively through traditional release testing. Additional analytical methods may be appropriate when established tests do not capture the attributes responsible for process variation. In one commercial antibody-manufacturing study, Fourier-transform infrared spectroscopy and partial-least-squares models were used to examine the relationship between raw material variability and productivity and to predict effects on biotherapeutic yields.⁷ Such tools will not be necessary for every input, but they illustrate how material data and manufacturing history can support more informed risk assessments for materials with demonstrated process sensitivity.

Materials derived from human or animal sources introduce additional considerations because their origin and biological variability can affect both safety and manufacturing consistency. In cell and gene therapy and tissue-engineered product manufacturing, relevant concerns include adventitious-agent transmission, infectious-disease risk, material identity, lot-to-lot consistency, and general material qualification. These materials can also affect final-product safety, potency, purity, and stability, depending on where and how they are used in the process.⁸

Biological origin can create variability that is difficult to manage through supplier naming conventions alone. Differences among serum lots, for example, may affect cellular growth or differentiation. Pooling can improve consistency for some blood-derived materials, but the degree of pooling may differ among suppliers or even among lots from the same supplier, and relevant attributes may still require testing to confirm that a new lot performs adequately in the manufacturing process. Material acceptance strategies must therefore reflect the intended use and the consequences of inconsistent performance.⁸

For products subject to applicable current good manufacturing practice (GMP) requirements, material management may include supplier qualification, defined acceptance criteria, quarantine before testing or examination and release, source documentation, and additional testing when supplier controls do not provide sufficient assurance. The same draft recommendations advise considering materials free of human- or animal-derived proteins when appropriate because they may carry fewer safety risks and may exhibit less compositional variability. That choice still requires process-specific evaluation; recombinant or animal-component-free alternatives are not automatically equivalent to the materials they replace.⁸

Some starting materials require resilience measures that differ from conventional supplier diversification. Master seed lots and master cell banks, and preferably working seed lots and working cell banks, should be stored at two or more controlled, separate sites to reduce the risk of total loss caused by a natural disaster, equipment malfunction, or human error. This approach protects a unique biological resource that may not be reproducible through ordinary repurchasing and should be supported by a defined contingency plan.⁹

Raw material security also encompasses the specialized components used to contain, transfer, filter, monitor, and store process fluids. Single-use systems (SUS) may include bags, filters, tubing, connectors, valves, storage bottles, and sensors, assembled individually or as integrated fluid paths. Although these products are often treated as consumables within purchasing systems, their design, construction materials, sterilization, and connection technologies can be closely tied to the validated manufacturing process.¹⁰

The risks associated with SUS extend beyond availability. Product adsorption, extractables and leachables, system fragility, manual connections, assembly complexity, holes, leakage, compromised integrity, and particle contamination all require assessment. A substitute component that appears commercially similar may differ in polymer composition, product-contact surface, sterilization history, connection geometry, or integrity under operating conditions. Those differences can matter even when the component performs the same general mechanical function.¹⁰

Supplier qualification must therefore consider the component and the controls used to produce and sterilize it. Sterility assurance for sterile SUS should be addressed during supplier qualification, and evidence of sterilization should be checked when units are received. Manufacturers must also evaluate product-contact interactions and extractable and leachable profiles, particularly for polymeric components, long contact times, or circumstances in which processed material may be absorbed by the system.¹⁰

Integrity must be maintained under the actual conditions in which the component will be processed and transported. Systems exposed to demanding conditions, including freezing and thawing, require attention to structural integrity and to the continued performance of sterile connection devices. Qualification of single-use bags and connectors should similarly address suitability, extractables, leachables, and integrity. These requirements make it difficult to treat an unavailable assembly or connector as a straightforward purchasing substitution.^9,10

Material disruption can originate at many points in the supply chain. Manufacturing or quality failures, increased demand, dependence on single or limited suppliers, reliance on foreign suppliers, natural disasters, transportation problems, and geopolitical events can all contribute to shortages. The affected input may be a raw material, ingredient, manufacturing component, or piece of equipment required to sustain production.¹¹

The COVID-19 vaccine scale-up provided a visible example of pressure across several input categories at once. Critical bottlenecks affected bioreactor bags, single-use assemblies, cell culture media, filters, lipids, vials, and stoppers, and shortages limited the ability of some production lines to operate at full capacity. The challenges during the pandemic demonstrated how expanding drug substance capacity alone cannot secure output when the supporting material network cannot expand at the same pace.¹²

Supplier concentration compounds that vulnerability. A decline in supplier numbers was strongly associated with shortages among the sterile injectable anti-infective and cardiovascular products evaluated in a 2012–2014 analysis. That finding cannot be extended quantitatively to all biologics, but it illustrates the general exposure created when the loss or failure of one source cannot be absorbed by the remaining market. Delays in raw materials and components are also recognized contributors to drug shortages, particularly when supplier capacity is already limited.^13,14

The immediate supplier list may still understate the actual concentration risk. Several direct suppliers can depend on the same upstream producer, specialized resin, film, precursor, sterilization provider, or component technology. Cell therapies offer a modality-specific example: their supply chains frequently rely on single-source providers and customized technologies available from a small number of manufacturers. A robust security assessment must look beyond whether two distributors or catalog numbers are available and determine whether the proposed sources are genuinely independent and technically substitutable.¹⁵

Commercial availability is not the same as interchangeability. A replacement raw material may differ in composition, impurity profile, functional performance, manufacturing process, or biological origin. A replacement component may introduce different product-contact materials, sterilization methods, extractable and leachable profiles, or connection characteristics. Each difference must be evaluated in the context of the process and product rather than accepted solely because the alternate serves the same general purpose.

GMP expectations require validation of significant changes to materials or equipment when those changes may affect product quality or process reproducibility. Supplier changes also pass through the pharmaceutical quality system, including assessment, approval, quality agreements or specifications, and appropriate incoming controls. A purchasing decision may therefore initiate technical evaluation, change control, qualification, validation, and regulatory assessment before the new material can support routine production.^3,16

The regulatory implications vary widely. The vaccine-manufacturing interchangeability analysis mentioned earlier estimated that about 10% of its 87 sampled inputs could require a full clinical trial process if replaced, approximately 35% could involve complex regulatory approvals lasting years, approximately 20% could involve approvals lasting months, and approximately 40% could require minor or no additional approval. These estimates apply only to that selected set of vaccine-manufacturing inputs, but the range illustrates why substitution plans must account for the specific material and its relationship to the registered process.¹

Regulators may expedite review when a shortage threatens supply, but a new source of a raw material, regulatory starting material, or active pharmaceutical material may still require approval. An alternate that has not been technically evaluated and incorporated into regulatory planning may offer little immediate protection after the primary source becomes unavailable. The strongest contingency is usually the one for which the analytical strategy, qualification work, and decision pathway have already been defined.¹¹

Comparability provides the framework for determining whether a manufacturing change has altered the resulting biological product in a way that could affect quality, safety, or efficacy. Pre-change and post-change products do not need to be identical in every measured attribute. They may be considered comparable when they are highly similar and the available knowledge is sufficiently predictive to conclude that observed differences will not adversely affect safety or efficacy.¹⁷

The evidence required depends on the risk and uncertainty introduced by the change. Comparability may rely on analytical testing, biological assays, process data, and, in some cases, nonclinical or clinical evidence. When analytical studies provide adequate assurance, additional nonclinical or clinical studies are not warranted. When differences are detected, the analytical methods cannot resolve relevant changes, or the relationship between quality attributes and clinical performance remains uncertain, further evidence may be appropriate.¹⁷

A new raw material may also expose gaps in the existing analytical control strategy. When established methods cannot measure the quality changes expected from the addition of a new material, additional analytical procedures may need to be developed. This creates another reason to study potential alternates before an urgent shortage. The manufacturer needs time not only to test the replacement but also to determine whether its current methods can detect the differences that matter.

For cell and gene therapy products, draft recommendations call for a detailed risk assessment of manufacturing changes involving materials and for comparability studies when a change may affect product quality. Higher-risk changes may require extensive analytical assessment, while lower-risk changes may support a more focused approach. Analytical studies alone may sometimes be insufficient, in which case nonclinical data or additional clinical studies may be needed. Because these recommendations remain draft and nonbinding, they should be applied within their stated scope, but they demonstrate the potential evidence burden associated with late or poorly characterized material changes.¹⁸

An effective program begins by identifying material criticality. The assessment should consider the effect of an interruption, the process sensitivity to lot variation, the availability of independent sources, the time required to qualify an alternate, and the potential regulatory consequences of substitution. A readily replaceable laboratory consumable does not warrant the same controls as a cell bank, a formulation-defining lipid, a process-sensitive media component, or a custom sterile assembly. The level of analysis, documentation, and mitigation should match the importance, complexity, and uncertainty of the risk.²

Supplier qualification should then reflect the material’s intended use and risk profile. Selection, qualification, approval, and ongoing maintenance of starting-material suppliers should be documented, with oversight proportionate to the material source, manufacturing process, supply-chain complexity, and final use. Quality requirements should be agreed with the supplier and documented through appropriate specifications or quality agreements, while supplier performance and incoming-material quality remain subject to monitoring.^3,16

Specifications must also capture the attributes that matter to the process. Broad catalog or compendial requirements may establish identity and general quality without fully controlling process-sensitive variation. Industry guidance recommends setting appropriate tolerances according to process sensitivity rather than creating restrictive limits without a scientific basis. For some materials, this may require closer alignment among the supplier’s controls, the manufacturer’s process understanding, and the attributes included in the purchasing specification.¹⁹

Traceability supports both prevention and investigation. End-to-end knowledge of the individual components used to manufacture an important input can help identify upstream sources of variability and common dependencies among apparently separate suppliers. Lot-specific raw material data can then be compared with process performance to determine whether changes in an upstream component are associated with altered manufacturing outcomes. This is particularly relevant for chemically defined media in which trace-element variability may originate from upstream materials that are not visible in the final media specification.²⁰

Supplier change notification is another essential control. Manufacturers need sufficient warning and appropriate supporting information to evaluate changes to a raw material, its manufacturing process, its site of production, or other characteristics that may influence performance. Industry guidance identifies relevant areas of supplier change and calls for supporting data and documentation to accompany notifications. Notification alone is not enough; the information must enter a defined change-control process that assigns responsibility for technical, quality, supply, and regulatory assessment.²¹

Lot monitoring can strengthen this system when applied selectively. Historical process data, analytical characterization, supplier information, and material genealogy may reveal relationships that remain invisible in batch-by-batch disposition. Spectroscopic and multivariate methods can help evaluate complex materials whose functional variation is not fully captured by routine testing, while simpler trending may be sufficient for other inputs. The approach should follow demonstrated material and process risk rather than an expectation that every incoming material undergo extensive characterization.^4,7

Contingency planning should distinguish a second commercial source from a qualified backup. A supplier listed in a sourcing database provides limited resilience if its material has not been tested in the process, its quality system has not been assessed, and the regulatory pathway for adoption remains undefined. For the most critical inputs, manufacturers should determine in advance what analytical testing, engineering work, process validation, stability evaluation, comparability assessment, and regulatory communication would be needed to introduce an alternate. The same planning should address unique biological banks and custom components for which ordinary dual sourcing may be impractical.

Raw material security requires a governance structure capable of connecting scientific, quality, regulatory, and commercial information. Interdisciplinary risk-management teams may include representatives from quality, product development, engineering, regulatory affairs, production, supply chain, clinical functions, and other relevant areas. Such a team can maintain the critical-material register, review supplier performance and change notifications, monitor emerging constraints, and ensure that technical and regulatory planning keeps pace with sourcing decisions.²

When a disruption occurs, the response should begin with a rapid assessment of the affected material, available inventory, exposed products and processes, alternate sources, and potential regulatory actions. Cell therapy supply chain recommendations emphasize coordinated assessment across laboratory operations, quality, clinical, regulatory, and other stakeholders rather than separate functional responses. The same principle applies more broadly: procurement may identify an alternate, but development and manufacturing must determine whether it will work, quality must determine how it can be qualified, and regulatory affairs must determine how the change must be documented or submitted.¹⁵

Clear responsibility is especially important when a sponsor works with a CDMO. The parties should define who selects and qualifies suppliers, purchases and stores materials, performs incoming testing, manages supplier notifications, retains samples, evaluates alternates, and communicates shortages. They should also understand whether the manufacturing strategy depends on platform materials, sponsor-specified inputs, or customized assemblies. Decisions made during development and technology transfer can determine how many substitution options remain later in the product life cycle.

Raw material security is strongest when continuity, material quality, process performance, and regulatory comparability are managed through the same decision framework. Inventory can create time, and supplier diversification can reduce exposure, but neither can replace process understanding or advance qualification. The most resilient manufacturing programs establish which materials matter, understand why they matter, and prepare the evidence needed to act before a disruption reaches the production schedule.

1. “How to Pave the Road to African Equity? An Insightful Material Supply Chain Market Research: Situation Assessment and Overview.” Coalition for Epidemic Preparedness Innovations. Feb. 2025.

2. ICH Harmonised Guideline: Quality Risk Management Q9(R1). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 18 Jan. 2023.

3. ICH Harmonised Tripartite Guideline: Pharmaceutical Quality System Q10. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 4 Jun. 2008.

4. McGillicuddy, Nicola, et al. “Examining the Sources of Variability in Cell Culture Media Used for Biopharmaceutical Production.” Biotechnology Letters. 40: 5–21 (2018).

5. Grinnell, Chris, et al. “Elemental Metal Variance in Cell Culture Raw Materials for Process Risk Profiling.” Biotechnology Progress. 36: e3004 (2020).

6. Bandyopadhyay, Arpan, et al. “Low-Molecular-Weight Impurity in Poloxamer 188 Responsible for Atypical Cell Culture Performance for mAb Production.” Journal of Biotechnology. 351: 13–22 (2022).

7. Pugh, Phyllis C, et al. “Predicting Raw Material Impact on Cell Culture Parameters in Commercial Biotherapeutic Manufacturing.” Biochemistry and Biophysics Reports. 43: 102192 (2025).

8. “Considerations for the Use of Human- and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products: Draft Guidance for Industry.” U.S. Food and Drug Administration. Apr. 2024.

9. “WHO Good Manufacturing Practices for Biological Products.” WHO Technical Report Series. No. 999, Annex 2. World Health Organization. 2016.

10. EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products. European Commission, Directorate-General for Health and Food Safety. 25 Aug. 2022.

11. “Supply Chain: FDA’s Role.” U.S. Food and Drug Administration. 16 Jan. 2025.

12. “CEPI Launches COVAX Marketplace to Match Buyers and Sellers of Critical Manufacturing Supplies and Speed Up Global Access to COVID-19 Vaccines Through COVAX.” Coalition for Epidemic Preparedness Innovations. 15 Jul. 2021.

13. “Drug Shortages: Certain Factors Are Strongly Associated with This Persistent Public Health Challenge.” U.S. Government Accountability Office. GAO-16-595. 7 July 2016.

14. “Frequently Asked Questions about Drug Shortages.” U.S. Food and Drug Administration. 18 Dec. 2024.

15. Killela, Patrick, et al. “Mitigation of Supply Chain Challenges in Cell Therapy Manufacturing: Perspectives from the Cord Blood Alliance.” Stem Cells Translational Medicine. 13: 843–847 (2024).

16. “EudraLex Volume 4, Part I, Chapter 5: Production.” European Commission. 13 Aug. 2014.

17. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process: Q5E. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. “ 18 Nov. 2004.

18. Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products: Draft Guidance for Industry. U.S. Food and Drug Administration. Jul. 2023.

19. “Raw Materials: Patient-Centric Requirements for the Supply of Raw Materials.” BioPhorum. 26 June 2015.

20. “Trace Element Variation for Chemically Defined Cell Culture Media: Biopharmaceutical Industry Requirements and Cross-Company Collaboration to Mitigate Risks.” BioPhorum. 24 Mar. 2022.

21. “Raw Materials: Supplier Change Notifications: Change Areas and Requirements.” BioPhorum. 28 June 2022.